NCT03897036View on ClinicalTrials.gov

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

January 25, 2024

Study Completion Date

January 25, 2024

Conditions

Carcinoma, Basal Cell

Interventions

DRUG

CX-4945

API powder-in-capsule in 200 mg strength

Trial Locations (6)

22031

Inova Schar Cancer Institute, Fairfax

33612

H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa

75246

Texas Oncology, P.A., Dallas

77030

University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado Anschutz Medical Campus, Aurora

85258

HonorHealth Research & Innovation Institute, Scottsdale

All Listed Sponsors

lead

Senhwa Biosciences, Inc.

INDUSTRY

NCT03897036 - Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) | Biotech Hunter | Biotech Hunter